Half of British doctors who received payments from the pharmaceutical industry last year remained anonymous.
In many if not most countries around the world, patients are still not being properly informed about the pharma links of their doctors and health workers. Illustrating how such conflicts of interest present a problem, a U.S. study published earlier this year found that oncologists may be more likely to prescribe particular cancer drugs when they receive payments from the companies that make them.
In another example, an investigation carried out in the UK in 2016 found that more than 130 officials employed in the country’s National Health Service (NHS) were simultaneously being paid as consultants by pharmaceutical companies. The officials concerned, most of whom are believed to be managers or other senior administrators, had been involved in assessing which drugs the NHS should give to patients.
Clearly, and as we have said many times before, the multinational pharmaceutical industry remains the biggest barrier to the people of the world achieving health.